Anselamimab

Anselamimab (CAEL-101) is a chimeric monoclonal antibody for systemic light chain (AL) amyloidosis. Anselamimab can promote phagocytic destruction and subsequent clearance of amyloid deposits. Anselamimab can be used in the research of amyloidosis[1][2].

Product Specifications

CAS Number

[2414866-63-8]

Product Name Alternative

CAEL-101

UNSPSC

12352203

Target

Amyloid-β; Apolipoprotein

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/anselamimab.html

Purity

98.96

Solubility

10 mM in DMSO|H2O

Smiles

[Anselamimab]

Molecular Weight

(144.42 kDa)

References & Citations

[1]Fu J, et al. Personalizing amyloidosis therapy with real time PET imaging of fibril-reactive monoclonal antibody cael-101. Blood, 2018, 132: 1003.|[2]Edwards CV, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138 (25) :2632-2641.